Results 21 to 30 of about 11,727 (181)

Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications

open access: yesApplied Sciences, 2022
Nonselective cell damage remains a significant limitation of radiation therapies in cancer. Decades of successful integration of radiation therapies with other medicinal chemistry strategies significantly improved therapeutic benefits in cancer ...
Arvind Negi   +2 more
doaj   +1 more source

Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis [PDF]

open access: yesBiomarker Research, 2014
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph'). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa
Martinez-Serra, Jordi   +12 more
openaire   +3 more sources

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)

open access: yesBMC Cancer, 2004
Background Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins.
Cano Pedro   +2 more
doaj   +1 more source

Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. [PDF]

open access: yesPLoS Computational Biology, 2009
Chromosomal translocations, which often generate chimeric proteins by fusing segments of two distinct genes, represent the single major genetic aberration leading to cancer.
Hedi Hegyi, László Buday, Peter Tompa
doaj   +1 more source

A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein [PDF]

open access: yesCommunications Biology, 2020
AbstractDrug resistance is of increasing concern, especially during the treatments of infectious diseases and cancer. To accelerate the drug discovery process in combating issues of drug resistance, here we developed a computational and experimental strategy to predict drug resistance mutations. Using BCR-ABL as a case study, we successfully recaptured
Jinxin Liu, Jianfeng Pei, Luhua Lai
openaire   +2 more sources

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

open access: yesReviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi   +2 more
doaj   +3 more sources

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]

open access: yes, 2010
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio   +71 more
core   +1 more source

Translational regulation of GPx-1 and GPx-4 by the mTOR pathway.

open access: yesPLoS ONE, 2014
Glutathione peroxidase activity was previously determined to be elevated in lymphocytes obtained from patients treated with the Bcr-Abl kinase inhibitor imatinib mesylate.
Emily N Reinke   +4 more
doaj   +1 more source

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients [PDF]

open access: yesArchive of Oncology, 2009
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion points of the derivative chromosome 9 and 22 in chronic myeloid leukemia in untreated patients and their follow up samples to correlate with disease ...
Bakshi Sonal R.   +8 more
doaj   +1 more source

Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay [PDF]

open access: yesBlood, 2008
Abstract The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor-risk subgroup of precursor B cell acute lymphoblastic leukemia (ALL), which represents 25–30% of adult ALL and 3–5% of childhood ALL.
Jacques JM van Dongen   +12 more
openaire   +1 more source

Home - About - Disclaimer - Privacy